The deal size was increased to $90M in common stock from $75M in common stock. Goldman Sachs, Leerink, Stifel, RBC Capital and William Blair acted as joint book running managers for the offering.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM:
- Contineum Therapeutics Submits Phase 2 Trial for PIPE-791
- Contineum offers to sell $75M in common stock
- Contineum price target lowered to $14 from $16 at Baird
- Contineum price target lowered to $22 from $25 at RBC Capital
- Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback